Interleukin 6

Source: Wikipedia, the free encyclopedia.
(Redirected from
Interleukin-6
)
IL6
Gene ontology
Molecular function
Cellular component
Biological process
Sources:Amigo / QuickGO
Ensembl

ENSG00000136244

ENSMUSG00000025746

UniProt

P05231

P08505

RefSeq (mRNA)

NM_000600
NM_001318095
NM_001371096

NM_031168
NM_001314054

RefSeq (protein)

NP_000591
NP_001305024
NP_001358025

NP_001300983
NP_112445

Location (UCSC)Chr 7: 22.73 – 22.73 MbChr 5: 30.22 – 30.22 Mb
PubMed search[3][4]
Wikidata
View/Edit HumanView/Edit Mouse

Interleukin 6 (IL-6) is an interleukin that acts as both a pro-inflammatory cytokine and an anti-inflammatory myokine. In humans, it is encoded by the IL6 gene.[5]

In addition,

IL-1ra and IL-10
.

There is some early evidence that IL-6 can be used as an

inflammatory marker for severe COVID-19 infection with poor prognosis, in the context of the wider coronavirus pandemic.[6]

Function

Immune system

IL-6 is secreted by

acute phase response
.

IL-6 is responsible for stimulating acute phase protein synthesis, as well as the production of

B cells and is antagonistic to regulatory T cells
.

Metabolic

It is capable of crossing the blood–brain barrier[7] and initiating synthesis of PGE2 in the hypothalamus, thereby changing the body's temperature setpoint. In muscle and fatty tissue, IL-6 stimulates energy mobilization that leads to increased body temperature. At 4 °C, both the oxygen consumption and core temperature were lower in IL-6-/- compared with wild-type mice, suggesting a lower cold-induced thermogenesis in IL-6-/- mice.[8]

In the absence of inflammation 10–35% of circulating IL-6 may come from adipose tissue.

adipocytes and is thought to be a reason why obese individuals have higher endogenous levels of CRP.[10] IL-6 may exert a tonic suppression of body fat in mature mice, given that IL-6 gene knockout causes mature onset obesity.[11][12][13] Moreover, IL-6 can suppress body fat mass via effects at the level of the CNS.[11] The antiobesity effect of IL-6 in rodents is exerted at the level of the brain, presumably the hypothalamus and the hindbrain.[14][15][16] On the other hand, enhanced central IL-6 trans-signaling may improve energy and glucose homeostasis in obesity[17] Trans-signaling implicates that a soluble form of IL-6R (sIL-6R) comprising the extracellular portion of the receptor can bind IL-6 with a similar affinity as the membrane bound IL-6R. The complex of IL-6 and sIL-6R can bind to gp130 on cells, which do not express the IL-6R, and which are unresponsive to IL-6.[17]

Studies in experimental animals indicate that IL-6 in the CNS partly mediates the suppression of food intake and body weight exerted by glucagon-like peptide-1 (GLP-1) receptor stimulation.[18]

Outside the CNS, it seems that IL-6 stimulates the production of GLP-1 in the endocrine pancreas and the gut.[19] Amylin is another substance that can reduce body weight, and that may interact with IL-6. Amylin-induced IL-6 production in the ventromedial hypothalamus (VMH) is a possible mechanism by which amylin treatment could interact with VMH leptin signaling to increase its effect on weight loss.[20]

It is assumed that interleukin 6 in the liver activates the homologue of the human longevity gene

citrate uptake and hepatic lipogenesis.[21][22]

Central nervous system

Intranasally administered IL-6 has been shown to improve sleep-associated consolidation of emotional memories.[23]

There are indications of interactions between GLP-1 and IL-6 in several parts of the brain. One example is the parabrachial nuclei of the pons, where GLP-1 increases IL-6 levels[24][25] and where IL-6 exerts a marked anti-obesity effect.[26]

Role as myokine

IL-6 is also considered a myokine, a cytokine produced from muscle, which is elevated in response to muscle contraction.[27] It is significantly elevated with exercise, and precedes the appearance of other cytokines in the circulation. During exercise, it is thought to act in a hormone-like manner to mobilize extracellular substrates and/or augment substrate delivery.[28]

Like in humans, there seems to be an increase in IL-6 expression in working muscle and plasma IL-6 concentration during exercise in rodents.[29][30] Studies in mice with IL-6 gene knockout indicate that lack of IL-6 in mice affect exercise function.[9]

It has been shown that the reduction of abdominal obesity by exercise in human adults can be reversed by the IL-6 receptor blocking antibody tocilizumab. Together with the findings that IL-6 prevents obesity, stimulates lipolysis and is released from skeletal muscle during exercise, the tocilizumab finding indicates that IL-6 is required for exercise to reduce visceral adipose tissue mass.[31] Bone may be another organ affected by exercise induced IL-6, given that muscle-derived interleukin 6 has been reported to increase exercise capacity by signaling in osteoblasts.[32]

IL-6 has extensive anti-inflammatory functions in its role as a myokine. IL-6 was the first myokine that was found to be secreted into the blood stream in response to muscle contractions.[33] Aerobic exercise provokes a systemic cytokine response, including, for example, IL-6, IL-1 receptor antagonist (IL-1ra), and IL-10. IL-6 was serendipitously discovered as a myokine because of the observation that it increased in an exponential fashion proportional to the length of exercise and the amount of muscle mass engaged in the exercise. It has been consistently demonstrated that the plasma concentration of IL-6 increases during muscular exercise. This increase is followed by the appearance of IL-1ra and the anti-inflammatory cytokine IL-10. In general, the cytokine response to exercise and sepsis differs with regard to TNF-α. Thus, the cytokine response to exercise is not preceded by an increase in plasma-TNF-α. Following exercise, the basal plasma IL-6 concentration may increase up to 100-fold, but less dramatic increases are more frequent. The exercise-induced increase of plasma IL-6 occurs in an exponential manner and the peak IL-6 level is reached at the end of the exercise or shortly thereafter. It is the combination of mode, intensity, and duration of the exercise that determines the magnitude of the exercise-induced increase of plasma IL-6.[34]

IL-6 had previously been classified as a proinflammatory cytokine. Therefore, it was first thought that the exercise-induced IL-6 response was related to muscle damage.[35] However, it has become evident that eccentric exercise is not associated with a larger increase in plasma IL-6 than exercise involving concentric "nondamaging" muscle contractions. This finding clearly demonstrates that muscle damage is not required to provoke an increase in plasma IL-6 during exercise. As a matter of fact, eccentric exercise may result in a delayed peak and a much slower decrease of plasma IL-6 during recovery.[34]

Recent work has shown that both upstream and downstream signalling pathways for IL-6 differ markedly between myocytes and macrophages. It appears that unlike IL-6 signalling in macrophages, which is dependent upon activation of the NFκB signalling pathway, intramuscular IL-6 expression is regulated by a network of signalling cascades, including the Ca2+/NFAT and glycogen/p38 MAPK pathways. Thus, when IL-6 is signalling in monocytes or macrophages, it creates a pro-inflammatory response, whereas IL-6 activation and signalling in muscle is totally independent of a preceding TNF-response or NFκB activation, and is anti-inflammatory.[36]

IL-6, among an increasing number of other recently identified myokines, thus remains an important topic in myokine research. It appears in muscle tissue and in the circulation during exercise at levels up to one hundred times basal rates, as noted, and is seen as having a beneficial impact on health and bodily functioning when elevated in response to

physical exercise.[37]

Receptor

Main article: Interleukin-6 receptor

IL-6 signals through a cell-surface

transcription factors, Janus kinases (JAKs) and Signal Transducers and Activators of Transcription (STATs).[38]

IL-6 is probably the best-studied of the cytokines that use

cardiotrophin-1 (CT-1), cardiotrophin-like cytokine (CLC), leukemia inhibitory factor (LIF), oncostatin M (OSM), Kaposi's sarcoma-associated herpesvirus interleukin 6-like protein (KSHV-IL6).[39] These cytokines are commonly referred to as the IL-6 like or gp130 utilising cytokines [40]

In addition to the membrane-bound receptor, a soluble form of IL-6R (sIL-6R) has been purified from human serum and urine. Many neuronal cells are unresponsive to stimulation by IL-6 alone, but differentiation and survival of neuronal cells can be mediated through the action of sIL-6R. The sIL-6R/IL-6 complex can stimulate neurites outgrowth and promote survival of neurons and, hence, may be important in nerve regeneration through remyelination.

Interactions

Interleukin-6 has been shown to

interact with interleukin-6 receptor,[41][42][43] glycoprotein 130,[44] and Galectin-3.[45]

There is considerable functional overlap and interaction between Substance P (SP), the natural ligand for the neurokinin type 1 receptor (NK1R, a mediator of immunomodulatory activity) and IL-6.

Role in disease

IL-6 stimulates the inflammatory and auto-immune processes in many diseases such as

systemic lupus erythematosus,[51] multiple myeloma,[52] prostate cancer,[53] Behçet's disease,[54] rheumatoid arthritis,[55] and intracerebral hemorrhage.[56]

Hence, there is an interest in developing

systemic juvenile idiopathic arthritis.[61] Others are in clinical trials.[62] It has been observed that genetic inactivation of ZCCHC 6 suppresses IL‐6 expression and reduces the severity of experimental osteoarthritis in Mice.[63] Some plant derived small molecule such as Butein have been reported to inhibit IL-6 expression in IL-1β stimulated human chondrocytes.[64]

Liver diseases

Since IL-6 is a well-known pleiotropic molecule, it plays a dual role in the pathogenesis of liver diseases. While it is necessary for promoting liver regeneration,[65] IL-6 is also a highly recognized marker of systemic inflammation and its association with mortality in liver diseases has been reported by multiple studies.[66][67][68][69][70] In patients with severe alcohol-associated hepatitis, IL-6 showed the most robust elevation among inflammatory cytokines compared to healthy controls with a further increase in non-survivors. In these patients, IL-6 was a predictor of short-term (28- and 90-day) mortality.[70]

Rheumatoid arthritis

The first FDA approved

anti-IL-6
treatment was for rheumatoid arthritis.

Cancer

autoimmune diseases, but due to the role of IL-6 in chronic inflammation, IL-6 blockade was also evaluated for cancer treatment.[71][72][73] IL-6 was seen to have roles in tumor microenvironment regulation,[74][73] production of breast cancer stem cell-like cells,[75] metastasis through down-regulation of E-cadherin,[76] and alteration of DNA methylation in oral cancer.[77]

Advanced/

metastatic cancer patients have higher levels of IL-6 in their blood.[78] One example of this is pancreatic cancer, with noted elevation of IL-6 present in patients correlating with poor survival rates.[79]

Diseases

Enterovirus 71

High IL-6 levels are associated with the development of encephalitis in children and immunodeficient mouse models infected with Enterovirus 71; this highly contagious virus normally causes a milder illness called Hand, foot, and mouth disease but can cause life-threatening encephalitis in some cases. EV71 patients with a certain gene polymorphism in IL-6 also appear to be more susceptible to developing encephalitis.

Epigenetic modifications

IL-6 has been shown to lead to several neurological diseases through its impact on

CpG islands on gene promoters, repressing the chromatin structure surrounding the DNA sequence and inhibiting transcriptional machinery from accessing the gene to induce transcription.[81] Increased IL-6, therefore, can hypermethylate DNA sequences and subsequently decrease gene expression through its effects on DNMT1 expression.[83]

Schizophrenia

The induction of epigenetic modification by IL-6 has been proposed as a mechanism in the pathology of schizophrenia through the hypermethylation and repression of the

GABA levels and on neural oscillations.[85] Neural oscillations occur when inhibitory GABAergic neurons fire synchronously and cause inhibition of a multitude of target excitatory neurons at the same time, leading to a cycle of inhibition and disinhibition.[85] These neural oscillations are impaired in schizophrenia, and these alterations may be responsible for both positive and negative symptoms of schizophrenia.[86]

Aging

IL-6 is commonly found in the senescence-associated secretory phenotype (SASP) factors secreted by senescent cells (a toxic cell-type that increases with aging).[87][88] Cancer (a disease that increases with age) invasiveness is promoted primarily though the actions of the SASP factors metalloproteinase, chemokine, IL-6, and interleukin 8 (IL-8).[89][87] IL-6 and IL-8 are the most conserved and robust features of SASP.[90]

Myelodysplastic Syndromes

IL-6 receptor was found upregulated in high-risk MDS patients. The inhibition of IL-6 signaling pathway can significantly ameliorate the clonogenicity of MDS hematopoietic stem and progenitor cells (HSPCs), but have undetectable effect on normal HSPCs.[73]

Depression and major depressive disorder

See also: Epigenetics of depression § Brain-derived neurotrophic factor, Epigenetics of schizophrenia#Methylation of BDNF

The epigenetic effects IL-6 have also been implicated in the pathology of depression. The effects of IL-6 on depression are mediated through the repression of brain-derived neurotrophic factor (BDNF) expression in the brain; DNMT1 hypermethylates the BDNF promoter and reduces BDNF levels.[91] Altered BDNF function has been implicated in depression,[92] which is likely due to epigenetic modification following IL-6 upregulation.[91] BDNF is a neurotrophic factor implicated in spine formation, density, and morphology on neurons.[93] Downregulation of BDNF, therefore, may cause decreased connectivity in the brain. Depression is marked by altered connectivity, in particular between the anterior cingulate cortex and several other limbic areas, such as the hippocampus.[94] The anterior cingulate cortex is responsible for detecting incongruences between expectation and perceived experience.[95] Altered connectivity of the anterior cingulate cortex in depression, therefore, may cause altered emotions following certain experiences, leading to depressive reactions.[95] This altered connectivity is mediated by IL-6 and its effect on epigenetic regulation of BDNF.[91]

Additional preclinical and clinical data, suggest that Substance P [SP] and IL-6 may act in concert to promote major depression. SP, a hybrid neurotransmitter-cytokine, is co-transmitted with BDNF through paleo-spinothalamic circuitry from the periphery with collaterals into key areas of the limbic system. However, both IL6 and SP mitigate expression of BDNF in brain regions associated with negative affect and memory. SP and IL6 both relax tight junctions of the blood brain barrier, such that effects seen in fMRI experiments with these molecules may be a bidirectional mix of neuronal, glial, capillary, synaptic, paracrine, or endocrine-like effects. At the cellular level, SP is noted to increase expression of interleukin-6 (IL-6) through PI-3K, p42/44 and p38 MAP kinase pathways. Data suggest that nuclear translocation of NF-κB regulates IL-6 overexpression in SP-stimulated cells.[96] This is of key interest as: 1) a meta-analysis indicates an association of major depressive disorder, C-reactive protein and IL6 plasma concentrations,[97] 2) NK1R antagonists [five molecules] studied by 3 independent groups in over 2000 patients from 1998 to 2013 validate the mechanism as dose-related, fully effective antidepressant, with a unique safety profile.[98][99] (see Summary of NK1RAs in Major Depression), 3) the preliminary observation that plasma concentrations of IL6 are elevated in depressed patients with cancer,[100] and 4) selective NK1RAs may eliminate endogenous SP stress-induced augmentation of IL-6 secretion pre-clinically.[101] These and many other reports suggest that a clinical study of a neutralizing IL-6 biological or drug based antagonist is likely warranted in patients with major depressive disorder, with or without co-morbid chronic inflammatory based illnesses; that the combination of NK1RAs and IL6 blockers may represent a new, potentially biomarkable approach to major depression, and possibly bipolar disorder.

The IL-6 antibody sirukumab is now undergoing clinical trials against major depressive disorder.[102]

Asthma

Obesity is a known risk factor in the development of severe asthma. Recent data suggests that the inflammation associated with obesity, potentially mediated by IL-6, plays a role in causing poor lung function and increased risk for developing asthma exacerbations.[103]

Protein superfamily

Interleukin is the main member of the IL-6 superfamily (

IL23A, and CLCF1. A viral version of IL6 is found in Kaposi's sarcoma-associated herpesvirus.[104]

References

  1. ^ a b c GRCh38: Ensembl release 89: ENSG00000136244 – Ensembl, May 2017
  2. ^ a b c GRCm38: Ensembl release 89: ENSMUSG00000025746 – Ensembl, May 2017
  3. ^ "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  4. ^ "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  5. PMID 3294161
    .
  6. ^ "Raised troponin and interleukin-6 levels are associated with a poor prognosis in COVID-19". Cardiac Rhythm News. 2 April 2020.
  7. S2CID 22712577
    .
  8. PMID 16455769
    .
  9. ^
    PMID 14988384
    .
  10. PMID 10217702
    .
  11. ^
    S2CID 7111589
    .
  12. S2CID 12970519
    .
  13. PMID 15191885
    .
  14. PMID 12054638
    .
  15. PMID 19902173
    .
  16. PMID 24523541
    .
  17. ^
    PMID 23136552
    .
  18. PMID 24048027
    .
  19. PMID 22037645
    .
  20. PMID 25409701
    .
  21. PMID 28133767
    .
  22. PMID 28596784
    .
  23. S2CID 38515607
    .
  24. PMID 25116706
    .
  25. S2CID 208014066
    .
  26. PMID 30865890
    .
  27. S2CID 26503323
    .
  28. S2CID 4776835
    .
  29. S2CID 260192304
    .
  30. PMID 11018114
    .
  31. PMID 30595477
    .
  32. PMID 32078586
    .
  33. S2CID 12601630
    .
  34. ^
    PMID 23897689
    .
  35. PMID 9130176
    .
  36. PMID 20224659
    .
  37. PMID 23663276
    .
  38. PMID 9716487
    .
  39. PMID 7632928
    .
  40. PMID 12773095
    .
  41. PMID 14557255
    .
  42. PMID 12643274
    .
  43. S2CID 41245022
    .
  44. PMID 15989626
    .
  45. PMID 29875102
    .
  46. ^
    PMID 28946890
    .
  47. PMID 16306329
    .
  48. PMID 17684929
    .
  49. S2CID 230209
    .
  50. S2CID 6544784
    .
  51. PMID 15230289
    .
  52. S2CID 44820455
    .
  53. PMID 11312117
    .
  54. PMID 23257520
    .
  55. S2CID 20188179
    .
  56. S2CID 85495400
    .
  57. S2CID 45421426
    .
  58. PMID 16899109
    .
  59. PMID 18625622
    .
  60. PMID 15998837
    .
  61. S2CID 21554759
    .
  62. ^ First IL-6–blocking drug nears approval for rare blood disorder, Nature Medicine, October 7, 2013
  63. PMID 30302948
    .
  64. S2CID 52166938
    .
  65. PMID 30658726
    .
  66. S2CID 4408167
    .
  67. PMID 32874059
    .
  68. PMID 2044224
    .
  69. PMID 33301825
    .
  70. ^
    PMID 37994498
    .
  71. PMID 26854213
    .
  72. PMID 25590298
    .
  73. ^
    PMID 35900794
    .
  74. PMID 22893706
    .
  75. PMID 22134360
    .
  76. PMID 24806843
    .
  77. PMID 21710491
    .
  78. ^ "Cancer Patients Typically Have Increased Interleukin-6 Levels". American Society of Clinical Oncology 2006 Annual Meeting, Abstracts 8632 and 8633. Medscape.com. 2006-06-26.
  79. S2CID 11019678
    .
  80. PMID 17913903
    .
  81. ^
    PMID 19029285
    .
  82. ^
    PMID 18204201
    .
  83. PMID 20354000
    .
  84. PMID 11074872
    .
  85. ^
    PMID 22806213
    .
  86. S2CID 205505539
    .
  87. ^
    PMID 19053174
    .
  88. PMID 28729727
    .
  89. PMID 30526772
    .
  90. S2CID 218912510
    .
  91. ^
    PMID 18536530
    .
  92. S2CID 23626890
    .
  93. S2CID 24889257
    .
  94. PMID 17210143
    .
  95. ^
    S2CID 35224855
    .
  96. PMID 14654230
    .
  97. PMID 26065825
    .
  98. S2CID 6523822
    .
  99. PMID 9733503
    .
  100. PMID 11481159
    .
  101. PMID 8642417
    .
  102. ^ Clinical trial number NCT02473289 for "An Efficacy and Safety Study of Sirukumab in Participants With Major Depressive Disorder." at ClinicalTrials.gov
  103. PMID 27283230
    .
  104. PMID 22490805
    .

External links
Retrieved from "https://en.wikipedia.org/w/index.php?title=Interleukin_6&oldid=1218073072"